A single gene-editing infusion from Verve Therapeutics permanently disabled the PCSK9 gene in the liver, reducing LDL cholesterol by an average of 62% in patients with inherited high cholesterol, with effects lasting at least six months.…
A new breakthrough could change how high cholesterol is treated, offering a powerful alternative to traditional drugs. Researchers have developed tiny DNA-based molecules that shut down PCSK9—a key protein that keeps “bad” LDL cholesterol circulating in…
